AR116631A1 - Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma - Google Patents

Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma

Info

Publication number
AR116631A1
AR116631A1 ARP190102893A ARP190102893A AR116631A1 AR 116631 A1 AR116631 A1 AR 116631A1 AR P190102893 A ARP190102893 A AR P190102893A AR P190102893 A ARP190102893 A AR P190102893A AR 116631 A1 AR116631 A1 AR 116631A1
Authority
AR
Argentina
Prior art keywords
per
amount
antigen
addition
ipv
Prior art date
Application number
ARP190102893A
Other languages
English (en)
Inventor
Anil Vyankatrao Shitole
Manohar Doddapaneni
Jaganathan Semburakkiannan Kilvani
Rakesh Kumar
Inder Jit Sharma
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of AR116631A1 publication Critical patent/AR116631A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Una composición inmunogénica multidosis totalmente líquida que comprende: (i) un toxoide diftérico, (D); (ii) un toxoide tetánico, (T); (iii) un pertussis de células enteras inactivo, (wP) o pertussis acelular, (aP); (iv) un antígeno de superficie del virus de la hepatitis B, (HBsAg); (v) un antígeno tipo b de Haemophilus influenzae, (Hib); (vi) un antígeno de virus de la polio inactivo, (IPV) donde IPV Tipo 1 está en una cantidad de 1 - 50 DU por 0,5 ml e IPV Tipo 3 en una cantidad de 1 - 50 DU por 0,5 ml; y (vii) una combinación de 2-fenoxietanol y al menos otro conservante. Reivindicación 54: Un proceso de fabricación de una composición inmunogénica multidosis totalmente líquida que comprende: (i) un toxoide diftérico, (D); (ii) un toxoide tetánico, (T); (iii) un pertussis de células enteras inactivo, (wP) o pertussis acelular, (aP); (iv) un antígeno de superficie del virus de la hepatitis B, (HBsAg); (v) un antígeno Haemophilus influenzae tipo b, (Hib); (vi) un antígeno de virus de la polio inactivado, (IPV) y (vii) una combinación de 2-fenoxietanol y al menos un éster de parabeno; el proceso que comprende las etapas de: a) adición de solución salina normal en un recipiente / contenedor de mezcla; b) adición del componente - I que comprende toxoide diftérico; c) adición del componente - II que comprende toxoide tetánico; d) adición del componente - III que comprende antígeno de pertussis de células enteras inactivado o pertussis acelular, (aP); e) adición del componente - IV que comprende antígeno de superficie de Hepatitis B; f) adición del componente - V que comprende antígeno Hib; g) adición del componente - VI que comprende antígeno IPV donde IPV tipo 1 (cepa Mahoney o cepa Sabin) en una cantidad de 1 - 50 DU por 0,5 ml; e IPV tipo 3 (cepa Saukett o cepa Sabin) en una cantidad de 1 - 50 DU por 0,5 ml; h) adición de una combinación de conservantes seleccionados de: 2-fenoxietanol en una cantidad de 1 a 6 mg por 0,5 ml (v/v) y metilparabeno en una cantidad de 0,1 - 1,5 mg por 0,5 ml (p/v); o 2-fenoxietanol en una cantidad de 1 a 6 mg por 0,5 ml (v/v) y propilparabeno en una cantidad de 0,05 - 0,2 mg por 0,5 ml (p/v); o 2-fenoxietanol en una cantidad de 1 a 6 mg por 0,5 ml (v/v), metilparabeno en una cantidad de 0,1 - 1,5 mg por 0,5 ml (p/v) y propilparabeno en una cantidad de 0,05 - 0,2 mg por 0,5 ml (p/v); i) ajuste de pH a 6,0 a 7,0 con hidróxido de sodio / carbonato de sodio; y j) adición de solución salina normal para llevar a volumen.
ARP190102893A 2018-10-12 2019-10-10 Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma AR116631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201821038850 2018-10-12

Publications (1)

Publication Number Publication Date
AR116631A1 true AR116631A1 (es) 2021-05-26

Family

ID=68542707

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102893A AR116631A1 (es) 2018-10-12 2019-10-10 Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma

Country Status (21)

Country Link
US (1) US12090195B2 (es)
EP (1) EP3863665A1 (es)
JP (1) JP7478144B2 (es)
KR (1) KR20210091158A (es)
CN (1) CN113164577B (es)
AR (1) AR116631A1 (es)
AU (1) AU2019359564A1 (es)
BR (1) BR112021006707A2 (es)
CA (1) CA3115803A1 (es)
CO (1) CO2021004556A2 (es)
EA (1) EA202190778A1 (es)
JO (1) JOP20190242A1 (es)
MD (1) MD4890B1 (es)
MX (1) MX2021004233A (es)
PE (1) PE20211648A1 (es)
PH (1) PH12021550812A1 (es)
SG (1) SG11202103622SA (es)
TW (1) TW202034948A (es)
UY (1) UY38412A (es)
WO (1) WO2020075184A1 (es)
ZA (1) ZA202103154B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN112316126B (zh) * 2020-10-29 2021-08-13 武汉生物制品研究所有限责任公司 一种氢氧化铝佐剂吸附百日咳菌毛(Fim)抗原制品的制备方法
CN116355083B (zh) * 2023-05-30 2023-09-08 国药中生生物技术研究院有限公司 特异性结合脊髓灰质炎病毒i型抗原的抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3485184B2 (ja) 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
UA40596C2 (uk) 1992-05-23 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини та спосіб її одержання
DK1082965T3 (da) 1995-06-23 2009-07-27 Glaxosmithkline Biolog Sa Et vaccinepræparat der omfatter et polysaccharidkonjugatantigen adsorberet på aluminiumphosphat
CA2278684C (en) 1997-02-06 2007-04-10 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
US6790445B1 (en) * 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
DE69735191T2 (de) 1997-09-15 2006-10-05 Sanofi Pasteur Msd Verfahren zur Herstellung multivalenter Impfstoffe
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
US20040258700A1 (en) 2003-06-23 2004-12-23 Frimann Tine Holland Vaccine formulation with a preservative
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) 2006-08-15 2006-09-27 Novartis Ag Processes
WO2008028957A2 (en) * 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
MX344751B (es) * 2007-11-23 2017-01-05 Shanghai Zerun Biotechnology Co Ltd Genes que codifican para la proteina l1 mayor de la capside del virus del papiloma humano y uso de los mismos.
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
US10092640B2 (en) 2011-01-05 2018-10-09 Bharat Biotech International Limited Combination heptavalent vaccine
CN102133396B (zh) * 2011-03-16 2013-10-16 中国人民解放军第三〇二医院 一种疫苗注射剂及其制备方法
MA42317B2 (fr) * 2015-09-16 2021-11-30 Lg Chemical Ltd Composition de vaccin combinée pour administration multiple
SG11201900365WA (en) 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
JOP20190242A1 (ar) * 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها

Also Published As

Publication number Publication date
MD4890B1 (ro) 2024-04-30
JP7478144B2 (ja) 2024-05-02
EP3863665A1 (en) 2021-08-18
CO2021004556A2 (es) 2021-04-30
BR112021006707A2 (pt) 2021-07-27
PH12021550812A1 (en) 2021-11-08
ZA202103154B (en) 2022-03-30
EA202190778A1 (ru) 2021-08-05
CN113164577A (zh) 2021-07-23
SG11202103622SA (en) 2021-05-28
CA3115803A1 (en) 2020-04-16
CN113164577B (zh) 2024-06-18
TW202034948A (zh) 2020-10-01
US12090195B2 (en) 2024-09-17
UY38412A (es) 2020-04-30
JOP20190242A1 (ar) 2020-04-12
WO2020075184A1 (en) 2020-04-16
US20210346483A1 (en) 2021-11-11
PE20211648A1 (es) 2021-08-24
MD20210028A2 (ro) 2021-11-30
KR20210091158A (ko) 2021-07-21
JP2022502469A (ja) 2022-01-11
AU2019359564A1 (en) 2021-06-03
MX2021004233A (es) 2021-08-16

Similar Documents

Publication Publication Date Title
AR116631A1 (es) Composición de vacuna combinada que comprende poliovirus inactivado de dosis reducida y método para preparar la misma
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
UY37811A (es) Una composición inmunogénica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparación de la misma
HRP20110431T1 (hr) Kombinirano cjepivo od inaktiviranog poliovirusa
Shih et al. Hepatitis B virus
BR0113307A (pt) Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado
AR041880A1 (es) Composicion inmunogena
KR950701822A (ko) 간염B 표면 항원 및 다른 항원으로 구성된 조합 백신(Combined vaccines comprising hepatitis B surface antigen and other antines)
UY26801A1 (es) Composición de vacuna
Zhang et al. Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis
BRPI0111830B8 (pt) método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
RU2006136212A (ru) КОМБИНИРОВАННЫЕ ВАКЦИНЫ С НИЗКОЙ ДОЗОЙ КОНЬЮГАТА Hib
NZ594482A (en) Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
MX2019002495A (es) Metodos para producir virus para la produccion de vacunas.
DK1028750T3 (da) Fremgangsmåde til fremstilling af multivalente vacciner
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20200004A1 (es) Composicion de vacuna multivalente novedosa
BRPI0411099A (pt) composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus
AR101256A1 (es) Composición vacunal que comprende ipv y ciclodextrinas
Andey et al. Conventional vaccination methods: Inactivated and live attenuated vaccines
UA95810C2 (uk) Інактивована поліовірусна вакцина
Cohen et al. Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries
WO2008094849A3 (en) Sugar immunogens
Irving et al. Global health in the UK's GP postgraduate curriculum
GB1101578A (en) Extracting pertussis antigen